Development of a preventive vaccine for Ebola virus infection in primates

Nancy J. Sullivan, Anthony Sanchez, Pierre E. Rollin, Zhi Yong Yang, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

Outbreaks of haemorrhagic fever caused by the Ebola virus are associated with high mortality rates that are a distinguishing feature of this human pathogen. The highest lethality is associated with the Zaire subtype, one of four strains identified to date. Its rapid progression allows little opportunity to develop natural immunity, and there is currently no effective anti-viral therapy. Therefore, vaccination offers a promising intervention to prevent infection and limit spread. Here we describe a highly effective vaccine strategy for Ebola virus infection in non-human primates. A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques. Challenge with a lethal dose of the highly pathogenic, wild-type, 1976 Mayinga strain of Ebola Zaire virus resulted in uniform infection in controls, who progressed to a moribund state and death in less than one week. In contrast, all vaccinated animals were asymptomatic for more than six months, with no detectable virus after the initial challenge. These findings demonstrate that it is possible to develop a preventive vaccine against Ebola virus infection in primates.

Original languageEnglish (US)
Pages (from-to)605-609
Number of pages5
JournalNature
Volume408
Issue number6812
DOIs
StatePublished - Nov 30 2000
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Primates
Vaccines
Democratic Republic of the Congo
Macaca
Viral Proteins
Humoral Immunity
Infection Control
Innate Immunity
Cellular Immunity
Disease Outbreaks
Immunization
Vaccination
Fever
Viruses
Mortality
DNA
Infection
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y., & Nabel, G. J. (2000). Development of a preventive vaccine for Ebola virus infection in primates. Nature, 408(6812), 605-609. https://doi.org/10.1038/35046108

Development of a preventive vaccine for Ebola virus infection in primates. / Sullivan, Nancy J.; Sanchez, Anthony; Rollin, Pierre E.; Yang, Zhi Yong; Nabel, Gary J.

In: Nature, Vol. 408, No. 6812, 30.11.2000, p. 605-609.

Research output: Contribution to journalArticle

Sullivan, NJ, Sanchez, A, Rollin, PE, Yang, ZY & Nabel, GJ 2000, 'Development of a preventive vaccine for Ebola virus infection in primates', Nature, vol. 408, no. 6812, pp. 605-609. https://doi.org/10.1038/35046108
Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 Nov 30;408(6812):605-609. https://doi.org/10.1038/35046108
Sullivan, Nancy J. ; Sanchez, Anthony ; Rollin, Pierre E. ; Yang, Zhi Yong ; Nabel, Gary J. / Development of a preventive vaccine for Ebola virus infection in primates. In: Nature. 2000 ; Vol. 408, No. 6812. pp. 605-609.
@article{a707b002d4d94371a718286520a348bb,
title = "Development of a preventive vaccine for Ebola virus infection in primates",
abstract = "Outbreaks of haemorrhagic fever caused by the Ebola virus are associated with high mortality rates that are a distinguishing feature of this human pathogen. The highest lethality is associated with the Zaire subtype, one of four strains identified to date. Its rapid progression allows little opportunity to develop natural immunity, and there is currently no effective anti-viral therapy. Therefore, vaccination offers a promising intervention to prevent infection and limit spread. Here we describe a highly effective vaccine strategy for Ebola virus infection in non-human primates. A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques. Challenge with a lethal dose of the highly pathogenic, wild-type, 1976 Mayinga strain of Ebola Zaire virus resulted in uniform infection in controls, who progressed to a moribund state and death in less than one week. In contrast, all vaccinated animals were asymptomatic for more than six months, with no detectable virus after the initial challenge. These findings demonstrate that it is possible to develop a preventive vaccine against Ebola virus infection in primates.",
author = "Sullivan, {Nancy J.} and Anthony Sanchez and Rollin, {Pierre E.} and Yang, {Zhi Yong} and Nabel, {Gary J.}",
year = "2000",
month = "11",
day = "30",
doi = "10.1038/35046108",
language = "English (US)",
volume = "408",
pages = "605--609",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6812",

}

TY - JOUR

T1 - Development of a preventive vaccine for Ebola virus infection in primates

AU - Sullivan, Nancy J.

AU - Sanchez, Anthony

AU - Rollin, Pierre E.

AU - Yang, Zhi Yong

AU - Nabel, Gary J.

PY - 2000/11/30

Y1 - 2000/11/30

N2 - Outbreaks of haemorrhagic fever caused by the Ebola virus are associated with high mortality rates that are a distinguishing feature of this human pathogen. The highest lethality is associated with the Zaire subtype, one of four strains identified to date. Its rapid progression allows little opportunity to develop natural immunity, and there is currently no effective anti-viral therapy. Therefore, vaccination offers a promising intervention to prevent infection and limit spread. Here we describe a highly effective vaccine strategy for Ebola virus infection in non-human primates. A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques. Challenge with a lethal dose of the highly pathogenic, wild-type, 1976 Mayinga strain of Ebola Zaire virus resulted in uniform infection in controls, who progressed to a moribund state and death in less than one week. In contrast, all vaccinated animals were asymptomatic for more than six months, with no detectable virus after the initial challenge. These findings demonstrate that it is possible to develop a preventive vaccine against Ebola virus infection in primates.

AB - Outbreaks of haemorrhagic fever caused by the Ebola virus are associated with high mortality rates that are a distinguishing feature of this human pathogen. The highest lethality is associated with the Zaire subtype, one of four strains identified to date. Its rapid progression allows little opportunity to develop natural immunity, and there is currently no effective anti-viral therapy. Therefore, vaccination offers a promising intervention to prevent infection and limit spread. Here we describe a highly effective vaccine strategy for Ebola virus infection in non-human primates. A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques. Challenge with a lethal dose of the highly pathogenic, wild-type, 1976 Mayinga strain of Ebola Zaire virus resulted in uniform infection in controls, who progressed to a moribund state and death in less than one week. In contrast, all vaccinated animals were asymptomatic for more than six months, with no detectable virus after the initial challenge. These findings demonstrate that it is possible to develop a preventive vaccine against Ebola virus infection in primates.

UR - http://www.scopus.com/inward/record.url?scp=0034735774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034735774&partnerID=8YFLogxK

U2 - 10.1038/35046108

DO - 10.1038/35046108

M3 - Article

C2 - 11117750

AN - SCOPUS:0034735774

VL - 408

SP - 605

EP - 609

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6812

ER -